host posted on July 19, 2011 11:14
The Lupus Foundation of America is dedicated to Bringing Down the Barriers that for decades have obstructed basic biomedical, clinical, epidemiological, behavioral, and translational research on lupus. We are committed to accelerating the pace of medical discovery in lupus with the clear goal of making clinical research more feasible. LFA is working through its Center for Clinical Trials Education (CCTE) and Lupus Research Registry to distribute information about clinical research studies currently seeking volunteers. As part of the LFA, the Arkansas Chapter, mission, we want to inform you of opportunities to learn more about clinical research participation and specific studies seeking participants in our community.
Clinical research studies are conducted to learn more about drugs that are in development (investigational drugs). All drugs must go through several phases of clinical research to evaluate their safety and effectiveness before they can be made available for use by the general population.
The EMBODY program is a global clinical research program testing the safety and effectiveness of an investigational study drug called epratuzumab in people with moderate to severe lupus. As part of the EMBODY program, two clinical research studies are being conducted at over 300 participating study sites in approximately 30 countries worldwide. Approximately 780 people are expected to participate in each study. To find out more information, including participants eligibility requirements, go to
www.EMBODYprogram.com and the LFA CCTE Study Spotlight at
http://www.lupus.org/clinicaltrials/study-spotlight.html.
Subtitle: Clinical research studies are conducted to learn more about drugs that are in development (investigational drugs).